Filing Analysis
Securities Offering
Filed Apr 16, 2026
HIGH
Achieve Life Sciences announced a massive $180 million private placement of common stock and warrants alongside a leadership transition, with CEO Richard Stewart stepping down and Andrew Goldberg being appointed as the new CEO.
Red Flags
- Extremely high dilution potential from the issuance of nearly 100 million shares and warrant shares.
- Coincidental departure of the sitting CEO at the time of a major capital raise and institutional entry.
Key Facts
- Entered into a Securities Purchase Agreement for the sale of 49,418,069 shares and 100,500 pre-funded warrants at $3.635 per unit.
- Issued accompanying warrants for 49,518,569 shares at an exercise price of $3.51, which could provide an additional $173.8 million in gross proceeds.
- Anticipated gross proceeds of $180.0 million to fund Phase 3 clinical trials for cytisinicline and commercialization efforts.
- CEO Richard Stewart to step down effective April 18, 2026, remaining on the Board; Andrew Goldberg appointed as CEO and President.
- New CEO Andrew Goldberg's compensation includes a $665,000 base salary and equity awards totaling approximately 9.5% of fully diluted capitalization, including performance-based units tied to 2x-9x share price milestones.
Regulation FD Disclosure
Filed Mar 24, 2026
LOW
Achieve Life Sciences, Inc. announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025. The disclosure was made via a press release on March 24, 2026, and furnished under Item 2.02.
Key Facts
- The company reported financial results for the period ending December 31, 2025.
- The report was filed on March 24, 2026.
- The financial information was furnished as Exhibit 99.1.
- The filing includes Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits).
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.